keyword
MENU ▼
Read by QxMD icon Read
search

Peripheral fatigue

keyword
https://www.readbyqxmd.com/read/28212620/clinical-manifestations-of-severe-enterovirus-71-infection-and-early-assessment-in-a-southern-china-population
#1
Si-da Yang, Pei-Qing Li, Yi-Min Li, Wei Li, Wen-Ying Lai, Cui-Ping Zhu, Jian-Ping Tao, Li Deng, Hong-Sheng Liu, Wen-Cheng Ma, Jia-Ming Lu, Yan Hong, Yu-Ting Liang, Jun Shen, Dan-Dan Hu, Yuan-Yuan Gao, Yi Zhou, Min-Xiong Situ, Yan-Ling Chen
BACKGROUND: Enterovirus 71 (EV-A71) shows a potential of rapid death, but the natural history of the infection is poorly known. This study aimed to examine the natural history of EV-A71 infection. METHODS: This was a prospective longitudinal observational study performed between January 1(st) and October 31(st), 2012, at three hospitals in Guangdong, China. Subjects with positive EV-A71 RNA laboratory test results were included. Disease progression was documented with MRI, autopsies, and follow-up...
February 17, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28209746/a-phase-ii-randomized-trial-go27827-of-first-line-folfox-plus-bevacizumab-with-or-without-the-met-inhibitor-onartuzumab-in-patients-with-metastatic-colorectal-cancer
#2
Johanna C Bendell, Howard Hochster, Lowell L Hart, Irfan Firdaus, Joseph R Mace, Joshua J McFarlane, Mark Kozloff, Daniel Catenacci, Jessie J Hsu, Stephen P Hack, David S Shames, See-Chun Phan, Hartmut Koeppen, Allen L Cohn
BACKGROUND: Dysregulated hepatocyte growth factor/mesenchymal-epithelial transition (MET) signaling is associated with poor prognosis and resistance to vascular endothelial growth factor inhibition in metastatic colorectal cancer (mCRC). We report outcomes from a double-blind, multicenter phase II trial of the MET inhibitor onartuzumab in combination with mFOLFOX-6 and bevacizumab for mCRC (GO27827; NCT01418222). MATERIALS AND METHODS: Patients were randomized 1:1 to receive onartuzumab (10 mg/kg intravenously [IV]) or placebo plus mFOLFOX-6 and bevacizumab (5 mg/kg IV)...
February 16, 2017: Oncologist
https://www.readbyqxmd.com/read/28209743/skeletal-muscle-bioenergetics-during-all-out-exercise-mechanistic-insight-into-the-oxygen-uptake-slow-component-and-neuromuscular-fatigue
#3
Ryan M Broxterman, Gwenael Layec, Thomas J Hureau, Markus Amann, Russell S Richardson
Although commonly used, the physiological mechanisms underlying all-out exercise performance are still unclear and an in-depth assessment of skeletal muscle bioenergetics is lacking. Therefore, phosphorous magnetic resonance spectroscopy ((31)P-MRS) was utilized to assess skeletal muscle bioenergetics during a 5-min all-out intermittent isometric knee-extensor protocol in 8 healthy men. The metabolic perturbation, adenosine triphosphate (ATP) synthesis rates, ATP cost of contraction, and mitochondrial capacity were determined from intramuscular concentrations of phosphocreatine (PCr), inorganic phosphate (Pi), diprotonated phosphate (H2PO4⁻ ), and pH...
February 16, 2017: Journal of Applied Physiology
https://www.readbyqxmd.com/read/28207951/endurance-capacity-and-neuromuscular-fatigue-following-high-vs-moderate-intensity-endurance-training-a-randomised-trial
#4
Thomas J O'Leary, Johnny Collett, Ken Howells, Martyn G Morris
High-intensity exercise induces significant central and peripheral fatigue, however the effect of endurance training on these mechanisms of fatigue is poorly understood. We compared the effect of cycling endurance training of disparate intensities on high-intensity exercise endurance capacity and the associated limiting central and peripheral fatigue mechanisms. Twenty adults were randomly assigned to 6 weeks of either high-intensity interval training (HIIT, 6-8 × 5 min at halfway between lactate threshold and maximal oxygen uptake [50%Δ]) or volume matched moderate-intensity continuous training (CONT, ~60-80 min at 90% lactate threshold)...
February 16, 2017: Scandinavian Journal of Medicine & Science in Sports
https://www.readbyqxmd.com/read/28204862/effect-of-constant-predictable-and-unpredictable-motor-tasks-on-motor-performance-and-blood-markers-of-stress
#5
Laura Kyguoliene, Albertas Skurvydas, Nerijus Eimantas, Neringa Baranauskienė, Dalia Mickeviciene, Daiva Urboniene, Margarita Cernych, Marius Brazaitis
An unfamiliar or novel physical stimulus induces activation of dopaminergic neurons within the brain and greater activity in areas involved in emotion; considering this, we aimed to establish whether unpredictable prolonged (fatiguing) motor task (vs. constant vs. predictable) evokes greater dopaminergic activity, enhances neuromuscular performance, motor accuracy, and perception of effort, and delays overall central fatigue. Fifteen healthy male volunteers (aged 22 ± 4 years) were required to perform 1 of 3 exercise trials (at least 1 week apart) of 100 intermittent isometric contraction (IIC) tasks involving knee extensions at 60° flexion...
February 16, 2017: Experimental Brain Research. Experimentelle Hirnforschung. Expérimentation Cérébrale
https://www.readbyqxmd.com/read/28177692/neuromuscular-manifestations-of-work-related-myalgia-in-women-specific-to-extensor-carpi-radialis-brevis
#6
Howard J Green, Don Ranney, Natasha Kyle, David Lounsbury, Ian C Smith, Riley Stewart, Melissa M Thomas, Heather Tick, A Russell Tupling
This study assessed neuromuscular function in the extensor carpi radialis brevis (ECRB) of female workers diagnosed with work-related myalgia (WRM, n=14, age 45.2±1.9 years) and the ECRB of healthy controls (CON, n=10, age 34.6±2.5 years). Groups were compared on voluntary and electrically evoked functional responses at rest (Pre), immediately following a 5 min repetitive task (Post-0) performed at 60% maximal voluntary contraction (MVC), and after 5 min of recovery (Post-5). Despite near complete motor unit activation (MUA)(CON 98±1% vs WRM 99±1%), at Pre, WRM produced 26% less (P<0...
November 24, 2016: Canadian Journal of Physiology and Pharmacology
https://www.readbyqxmd.com/read/28174169/altered-blood-flow-response-to-small-muscle-mass-exercise-in-cancer-survivors-treated-with-adjuvant-therapy
#7
Kaylin D Didier, Austin K Ederer, Landon K Reiter, Michael Brown, Rachel Hardy, Jacob Caldwell, Christopher Black, Michael G Bemben, Carl J Ade
BACKGROUND: Adjuvant cancer treatments have been shown to decrease cardiac function. In addition to changes in cardiovascular risk, there are several additional functional consequences including decreases in exercise capacity and increased incidence of cancer-related fatigue. However, the effects of adjuvant cancer treatment on peripheral vascular function during exercise in cancer survivors have not been well documented. We investigated the vascular responses to exercise in cancer survivors previously treated with adjuvant cancer therapies...
February 7, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/28160084/neuromuscular-adaptations-to-sprint-interval-training-and-the-effect-of-mammalian-omega-3-fatty-acid-supplementation
#8
Evan J H Lewis, Frédéric Stucky, Peter W Radonic, Adam H Metherel, Thomas M S Wolever, Greg D Wells
PURPOSE: Sprint interval training (SIT) stimulates rapid metabolic adaptations within skeletal muscle but the nature of neuromuscular adaptions is unknown. Omega-3 polyunsaturated fatty acids (N-3 PUFA) are suggested to enhance neuromuscular adaptations to exercise. METHODS: We measured the neuromuscular adaptations to SIT (Study-1) and conducted a placebo-controlled randomized double blinded study to determine the effect of N-3 PUFA supplementation on neuromuscular adaptations to SIT (Study-2)...
February 3, 2017: European Journal of Applied Physiology
https://www.readbyqxmd.com/read/28156643/pilot-study-of-minocycline-for-the-prevention-of-paclitaxel-associated-neuropathy-accru-ru221408i
#9
Travis J Dockter, Patricia J Zekan, Briant Fruth, Kathryn Jean Ruddy, Lauren E Ta, Todor Dentchev, Nguyet Le-Lindqwister, William M Sikov, Charles L Loprinzi
: 220 Background: Paclitaxel is associated with both an acute pain syndrome (P-APS) and chronic chemotherapy-induced peripheral neuropathy (CIPN). Preliminary animal data suggest that minocycline may be effective for the prevention of chemotherapy-induced neurotoxicity. The purpose of this pilot study was to investigate the efficacy of minocycline for the prevention of CIPN and P-APS. METHODS: Patients with breast cancer were enrolled prior to initiating neoadjuvant or adjuvant weekly paclitaxel for 12 weeks...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28156639/determining-priority-symptoms-of-women-with-recurrent-ovarian-cancers-a-gynecologic-oncology-group-study
#10
Lari B Wenzel, Sandra Ward, Susan M Sereika, Robert P Edwards, Michael Spring, Catherine M Bender, Richard T Penson, Teresa Hagan
: 101 Background: The purpose of this study is to recommend a core set of priority symptoms to be assessed in research and clinical settings for women with recurrent ovarian cancers. METHODS: We used baseline data of 497 women with recurrent ovarian, fallopian, or primary peritoneal cancer participating in a symptom management randomized clinical trial (GOG-0259) to identify a core index of patient-reported priority symptoms. We used the Symptom Representation Questionnaire to assess priority rankings of 28 symptoms based on four criteria: (1) symptom prevalence, (2) patient-reported symptom severity, (3) percentage of women identifying each symptom as one of top three symptoms "I would like to get better control over", and (4) the association between symptom severity and functional wellbeing as measured by the Functional Assessment of Cancer Therapy - Ovarian...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28152546/a-phase-1-dose-escalation-and-expansion-study-of-binimetinib-mek162-a-potent-and-selective-oral-mek1-2-inhibitor
#11
Johanna C Bendell, Milind Javle, Tanios S Bekaii-Saab, Richard S Finn, Zev A Wainberg, Daniel A Laheru, Colin D Weekes, Benjamin R Tan, Gazala N Khan, Mark M Zalupski, Jeffrey R Infante, Suzanne Jones, Kyriakos P Papadopoulos, Anthony W Tolcher, Renae E Chavira, Janna L Christy-Bittel, Emma Barrett, Amita Patnaik
BACKGROUND: Binimetinib (MEK162; ARRY-438162) is a potent and selective oral MEK 1/2 inhibitor. This phase 1 study determined the maximum tolerated dose (MTD), safety, pharmacokinetic and pharmacodynamic profiles, and preliminary anti-tumour activity of binimetinib in patients with advanced solid tumours, with expansion cohorts of patients with biliary cancer or KRAS- or BRAF-mutant colorectal cancer. METHODS: Binimetinib was administered twice daily. Expansion cohorts were enroled after MTD determination following a 3+3 dose-escalation design...
February 2, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28140719/phase-i-ii-study-of-the-novel-proteasome-inhibitor-delanzomib-cep-18770-for-relapsed-and-refractory-multiple-myeloma
#12
Dan T Vogl, Thomas G Martin, Ravi Vij, Parameswaran Hari, Joseph R Mikhael, David Siegel, Ka Lung Wu, Michel Delforge, Cristina Gasparetto
Delanzomib (CEP-18770), a reversible P2 threonine boronic acid proteasome (β5/β1 subunits) inhibitor that showed promising anti-myeloma effects in preclinical studies, was investigated in a single-agent multicenter phase I/II study in patients with relapsed/refractory myeloma. Sixty-one patients (17 during dose escalation; 44 in the expansion cohort) received delanzomib on days 1, 8, and 15 in 28-d cycles; 47 received the maximum tolerated dose (MTD), 2.1 mg/m(2). Dose-limiting toxicities (DLTs) at 2.4 mg/m(2) were rash and thrombocytopenia...
January 31, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28133180/-combination-chemotherapy-using-oxaliplatin-plus-s-1-for-well-advanced-gastric-cancer
#13
Hiroyuki Saito, Yuki Suematsu, Shunsuke Yamagishi, Miyuki Takahashi, Mao Nakayama, Michiko Fukabori, Akihiko Morita, Kazuhiko Wakabayashi, Yutaka Itoh
We studied the clinical efficacy of pre-operative combination chemotherapy using S-1 plus oxaliplatin for advanced gastric cancer. Four patients hadclinical Stage IV disease, 1 patient had clinical Stage III C disease, 2 patients had clinical Stage III B disease, and 1 patient had clinical Stage III A disease. The patients received 2-8 courses of oxaliplatin(130mg/m2)on day 1, andS -1 on days 1-14 every 3 weeks. The response rate was 56%(5 PR, 1 PD, and2 SD), andthe disease control rate was 88%. Toxicities were Grade 2 anemia, Grade 1 peripheral neuropathy, Grade 1 fatigue, and anorexia...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28133095/-nab-paclitaxel-plus-gemcitabine-hydrochloride-in-patients-with-metastatic-or-recurrent-pancreatic-cancer-a-single-institution-experience
#14
Yutaka Takeda, Yoshiteru Katsura, Yoshiaki Ohmura, Takuya Sakamoto, Yasuki Akiyama, Ryuichi Kuwahara, Yoshihiro Morimoto, Tomo Ishida, Yasuo Oneda, Kouhei Murakami, Atsushi Naito, Yoshinori Kagawa, Atsushi Takeno, Takeshi Kato, Shigeyuki Tamura
BACKGROUND: Pancreatic adenocarcinoma is one of the leading causes of cancer deaths in Japan.Albumin -bound paclitaxel (nab-paclitaxel)plus gemcitabine hydrochloride(GEM)combination chemotherapy provided significant improvements in the overall and progression-free survival in a phase III trial in Europe and America and a phase II trial in Japan.As a result, this combination therapy was approved for use in Japan. METHODS: We evaluated the efficacy of nab-paclitaxel plus GEM with metastatic or recurrent pancreatic cancer...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28132977/mitochondrial-trifunctional-protein-deficiency-an-adult-patient-with-similar-progress-to-charcot-marie-tooth-disease
#15
Yuki Yamamoto, Naoko Matsui, Yu Hiramatsu, Yoshimichi Miyazaki, Hiroyuki Nodera, Yuishin Izumi, Hiroshi Takashima, Ryuji Kaji
A 45-year-old man presented to us due to slowly progressive muscle weakness and sensory disturbances in his lower limbs since his 40's. He reported multiple episodes of exercise-induced severe muscle fatigue and brown urine in his childhood, which disappeared by age 20. A nerve conduction study showed peripheral axonal neuropathy and then Charcot-Marie-Tooth disease (CMT) was considered as the most likely diagnosis; however, exome sequencing failed to identify a mutation in the known genes of CMTs. Since age 55, he recurrently developed severe rhabdomyolysis that required hospitalization...
January 28, 2017: Rinshō Shinkeigaku, Clinical Neurology
https://www.readbyqxmd.com/read/28131211/potential-pathophysiological-pathways-that-can-explain-the-positive-effects-of-exercise-on-fatigue-in-multiple-sclerosis-a-scoping-review
#16
REVIEW
Martin Langeskov-Christensen, Etienne J Bisson, Marcia L Finlayson, Ulrik Dalgas
BACKGROUND: Fatigue is one of the most common and most disabling symptoms of multiple sclerosis (MS). It is a multidimensional and complex symptom with multifaceted origins, involving both central and peripheral fatigue mechanisms. Exercise has proven to be safe for people with MS, with cumulating evidence supporting significant reductions in fatigue. However, the potential pathophysiological pathways that can explain the positive effects of exercise on fatigue in MS remain elusive. OBJECTIVES: The objectives were, in PwMS (1) to update the knowledge on the pathophysiology underlying primary and secondary fatigue, and (2) to discuss potential pathophysiological pathways that can explain the positive effects of exercise on MS fatigue...
February 15, 2017: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/28123123/-acute-phase-reaction-following-bisphosphonates
#17
Hiroshi Tsurukami
Bisphosphonates are effective in decreasing bone resorption, the incidence of fragility fracure, and pain from bone metastases. Although relatively well tolerated, the initial dose(s)of intravenous or oral monthly aminobisphosphonates can be associated with an acute phase response, a nonspecific physiologic reaction associated with increased levels of inflammatory cytokines, fever, and flu like symptoms including fatigue, nausea, and myalgia within 3 days of dosing and lasting 7 days or less. Nitrogen-BPs(N-BPs)inhibit osteoclast function by acting as potent inhibitors of the enzyme farnesyl diphosphate(FPP)synthase in the mevalonate biosynthetic pathway...
2017: Clinical Calcium
https://www.readbyqxmd.com/read/28121808/perceived-exertion-during-muscle-fatigue-as-reflected-in-movement-related-cortical-potentials-an-event-related-potential-study
#18
Feng Guo, Yong-Jun Sun, Ri-Hui Zhang
The aim of this study was to explore the mechanism on perceived exertion during muscle fatigue. A total of 15 individuals in the fatigue group and 13 individuals in the nonfatigue group were recruited into this study, performing 200 intermittent handgrip contractions with 30% maximal voluntary contraction. The force, surface electromyography (sEMG), movement-related cortical potentials (MRCPs), and rating perception of effort (RPE) were combined to evaluate the perceived exertion during muscle fatigue. The maximal handgrip force significantly decreased (P<0...
February 8, 2017: Neuroreport
https://www.readbyqxmd.com/read/28119295/first-in-human-phase-1-study-of-margetuximab-mgah22-an-fc-modified-chimeric-monoclonal-antibody-in-patients-with-her2-positive-advanced-solid-tumors
#19
Y J Bang, G Giaccone, S A Im, D Y Oh, T M Bauer, J L Nordstrom, H Li, G R Chichili, P A Moore, S Hong, S J Stewart, J E Baughman, R J Lechleider, H A Burris
BACKGROUND: Margetuximab is an anti-HER2 antibody that binds with elevated affinity to both the lower and higher affinity forms of CD16A, an Fc-receptor important for antibody dependent cell-mediated cytotoxicity (ADCC) against tumor cells. A Phase 1 study was initiated to evaluate the toxicity profile, maximum tolerated dose (MTD), pharmacokinetics, and antitumor activity of margetuximab in patients with HER2-overexpressing carcinomas. PATIENTS AND METHODS: Patients with HER2-positive breast or gastric cancer, or other carcinomas that overexpress HER2, for whom no standard therapy was available, were treated with margetuximab by intravenous infusion at doses of 0...
January 24, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28119041/a-multi-center-open-label-randomized-phase-iii-trial-of-first-line-chemotherapy-with-capecitabine-monotherapy-versus-capecitabine-plus-oxaliplatin-in-elderly-patients-with-advanced-gastric-cancer
#20
In Gyu Hwang, Jun Ho Ji, Jung Hun Kang, Hyo Rak Lee, Hui-Young Lee, Kyong-Choun Chi, Suk Won Park, Su Jin Lee, Seung Tae Kim, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang
OBJECTIVES: More than half of cases of gastric cancer (GC) are diagnosed in elderly patients (≥70years). While doublet combination with fluoropyrimidines and platinum is currently considered standard first-line chemotherapy in advanced GC, the main goal of chemotherapy remains palliation. MATERIALS AND METHODS: In a multi-center phase III trial, patients with chemotherapy-naïve, metastatic GC, aged 70years or older were randomized 1:1 to receive X monotherapy (capecitabine 1000mg/m(2) bid po on days one to fourteen) or XELOX (X plus oxaliplatin 110mg/m(2) iv on D1)...
January 21, 2017: Journal of Geriatric Oncology
keyword
keyword
60246
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"